Haemonetics
257 hedge funds and large institutions have $2.66B invested in Haemonetics in 2021 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 88 increasing their positions, 81 reducing their positions, and 40 closing their positions.
320% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $3.77M
40% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 40
5% more funds holding
Funds holding: 245 → 257 (+12)
9% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 81
1.55% less ownership
Funds ownership: 99.55% → 97.99% (-1.6%)
26% less capital invested
Capital invested by funds: $3.58B → $2.66B (-$923M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$55.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$50.5M |
| 3 |
RRAM
River Road Asset Management
Louisville,
Kentucky
|
+$23.6M |
| 4 |
Morgan Stanley
New York
|
+$14.8M |
| 5 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$46.4M |
| 2 |
Millennium Management
New York
|
-$36.5M |
| 3 |
BPCM
Beach Point Capital Management
Santa Monica,
California
|
-$24.9M |
| 4 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$24.2M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$18.9M |
HAE Hedge Fund Activity: Q4 2021 in Review
257 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2021, worth a combined $2.66B — down 26% from $3.58B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new HAE positions and 40 closed out — a net gain of 16 holders — while 88 added to existing stakes and 81 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $55.8M. The largest seller was Janus Henderson Group, cutting an estimated $46.4M.
- 257 institutional investors held Haemonetics (HAE) as of Q4 2021, up from 245 in Q3 2021.
- Funds reported $2.66B of Haemonetics stock for Q4 2021, down 26% quarter-over-quarter.
- 56 funds opened new Haemonetics positions in Q4 2021 and 40 closed out, a net change of +16 holders.
- The largest Haemonetics buyer in Q4 2021 was Capital Research Global Investors, an estimated $55.8M added.
- The largest Haemonetics seller in Q4 2021 was Janus Henderson Group, an estimated $46.4M sold.
Based on aggregated 13F filings for Q4 2021.